68Ga-Labeled Magnetic-NIR Persistent Luminescent Hybrid Mesoporous Nanoparticles for Multimodal Imaging-Guided Chemotherapy and Photodynamic Therapy

ACS Appl Mater Interfaces. 2021 Mar 3;13(8):9667-9680. doi: 10.1021/acsami.0c21623. Epub 2021 Feb 22.

Abstract

Featured with a zero-autofluorescence background, superior signal-to-noise ratio, high sensitivity, and deep penetration ability, near-infrared persistent luminescence nanoparticle (NIR-PLNP)-based multimodal nanoprobes show great potential for full-scale noninvasive cancer diagnosis. However, direct synthesis of NIR-PLNP-based multimodal nanoprobes with high drug loading capacity to meet growing cancer theranostic demands remains a challenge. In this work, multifunctional hybrid mesoporous nanoparticles (HMNPs) that integrate NIR-PLNPs (Ga2O3:Cr3+, Nd3+), magnetic nanoparticles (Gd2O3), and radionuclides (68Ga) are designed and constructed via a large-pore (mesoporous silica nanoparticle) MSN-templated strategy. The ingenious composition design endows HMNPs with rechargeable NIR-PL, superior longitudinal relaxivity, and excellent radioactivity, making these versatile nanoparticles available for long-term in vivo NIR-PL imaging, magnetic resonance imaging (MRI), and positron emission tomography (PET) imaging. More importantly, the application of large-pore MSN templates maintains the mesoporous structure of HMNPs, promising excellent drug loading capacity of these nanoparticles. As a proof-of-concept, HMNPs loaded with a high dose of DOX (chemotherapy agent) and Si-Pc (photosensitizer) are rationally designed for chemotherapy and NIR-PL-sensitized photodynamic therapy (PDT), respectively. Studies with mice tumor models demonstrate that the DOX/Si-Pc-loaded HMNPs possess excellent cancer cell killing ability and an outstanding tumor suppression effect without systemic toxicity. This work shows the great potential of HMNPs as an "all-in-one" nanotheranostic tool for multimodal NIR-PL/MR/PET imaging-guided chemotherapy and NIR-PL-sensitized photodynamic cancer therapy and provides an innovative paradigm for the development of NIR-PLNP-based nanoplatforms in cancer theranostic.

Keywords: chemotherapy; drug loading; hybrid mesoporous nanoparticles; near-infrared persistent luminescence; photodynamic therapy; tumor multimodal imaging.

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Cell Line, Tumor
  • Chromium / chemistry
  • Chromium / therapeutic use
  • Doxorubicin / therapeutic use*
  • Drug Carriers / chemistry
  • Drug Carriers / therapeutic use*
  • Fluorescent Dyes / chemistry
  • Fluorescent Dyes / therapeutic use
  • Gallium / chemistry
  • Gallium / therapeutic use
  • Gallium Radioisotopes / chemistry
  • Humans
  • Indoles / radiation effects
  • Indoles / therapeutic use
  • Infrared Rays
  • Male
  • Metal Nanoparticles / chemistry
  • Metal Nanoparticles / therapeutic use*
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Multimodal Imaging
  • Neodymium / chemistry
  • Neodymium / therapeutic use
  • Neoplasms / diagnostic imaging*
  • Neoplasms / drug therapy*
  • Neoplasms / pathology
  • Organosilicon Compounds / radiation effects
  • Organosilicon Compounds / therapeutic use
  • Photochemotherapy
  • Photosensitizing Agents / radiation effects
  • Photosensitizing Agents / therapeutic use
  • Porosity
  • Precision Medicine / methods
  • Proof of Concept Study

Substances

  • Antineoplastic Agents
  • Drug Carriers
  • Fluorescent Dyes
  • Gallium Radioisotopes
  • Indoles
  • Organosilicon Compounds
  • Photosensitizing Agents
  • Chromium
  • silicon phthalocyanine
  • Neodymium
  • gallium oxide
  • Doxorubicin
  • Gallium-68
  • Gallium